The 2018 ASCO Annual Meeting took place June 1-5 in Chicago, Illinois.
Photo by ©ASCO/Rodney White 2017

T-cell therapy induced CMRs with no CRS

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
A novel CD19-targeted T-cell therapy induced complete metabolic responses (CMRs) and no cytokine release syndrome (CRS) in patients with B-cell lymphomas in a first-in-human clinical study. All subjects achieving CMR at the 1-month safety and efficacy assessment continued to show CMR at 3 months, investigators reported at... [Read Article]
Print Friendly, PDF & Email

Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at 2018 ASCO Annual Meeting
©ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 ASCO Annual Meeting. The analysis, based on bone marrow samples from patients with relapsed/refractory B-cell acute lymphoblastic... [Read Article]
Print Friendly, PDF & Email

Peripheral blood MRD correlates with treatment benefit in CLL

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL), according to a further examination of the phase 3 MURANO study. The new results show higher concordance in MRD-negativity between bone marrow and peripheral blood in patients... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of whether patients were exposed to... [Read Article]
Print Friendly, PDF & Email

Interim PET scans identify HL patients with better outcomes

Print Friendly, PDF & Email


Micrograph showing Hodgkin lymphoma
Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after upfront BEACOPP without impairing disease control, according to final results of the AHL2011-LYSA study. BEACOPP, compared to ABVD, improves progression-free survival (PFS) but not overall survival (OS) and is associated... [Read Article]
Print Friendly, PDF & Email

Ivosidenib active in R/R IDH1-mutated AML patients

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall response rate of 42% in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML) and IDH1 mutation, according to investigators. In addition, overall survival (OS) in patients... [Read Article]
Print Friendly, PDF & Email

Ibrutinib and venetoclax combo promising in frontline CLL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic leukemia (CLL), according to investigators for the CAPTIVATE study. In the first 30 patients, 77% of treatment-naïve patients had undetected minimal residual disease (MRD) in... [Read Article]
Print Friendly, PDF & Email

Chemo-free combo provides potential first-line option for FL

Print Friendly, PDF & Email


Attendee at ASCO 2018
©ASCO/Scott Morgan 2018
A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma (FL). According to investigators, the multicenter, international phase 3 RELEVANCE trial is the first to evaluate the... [Read Article]
Print Friendly, PDF & Email

bb2121 demonstrates durable responses, manageable toxicity in MM

Print Friendly, PDF & Email


Noopur S. Raje, MD
Photo by Andrew D. Bowser
bb2121, the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, induced deep and durable ongoing responses in heavily pretreated multiple myeloma (MM) patients, updated results of a phase 1 study show. At active doses (≥150 x 108 CAR+ T cells), the B-cell maturation antigen (BCMA)-targeted therapy produced... [Read Article]
Print Friendly, PDF & Email

Pomalidomide triplet significantly extends PFS in R/R MM

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
The addition of pomalidomide to bortezomib and low‐dose dexamethasone (PVd) significantly improves progression-free survival (PFS) in lenalidomide-exposed patients with relapsed or refractory (R/R) multiple myeloma (MM), a new study reveals. Up until now, pomalidomide and dexamethasone (Pd) had been the only therapy investigated exclusively after lenalidomide therapy,... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a phase 2 study. By contrast, there were no such improvements in a cohort of follicular lymphoma (FL)... [Read Article]
Print Friendly, PDF & Email

Two agents could take AML therapy in new directions

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Rodney White 2018
Two agents targeting novel pathways in myeloid malignancies—mivebresib and bencentinib—are showing promise in early studies, according to a speaker at the 2018 ASCO Annual Meeting. “Both BET and AXL inhibition appear to be new and exciting targets in myeloid malignancies,” said Alice S. Mims, MD, and both... [Read Article]
Print Friendly, PDF & Email

Single-agent acalabrutinib ‘impressive’ in patients with WM

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD, reported at the 2018 ASCO Annual Meeting. The BTK inhibitor was effective in both treatment-naïve and relapsed/refractory patients, with overall response rates for both groups in excess of 90%,... [Read Article]
Print Friendly, PDF & Email

Once-weekly carfilzomib combo improves PFS in R/R MM

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Michael R. Schmidt
A once-weekly regimen of carfilzomib plus dexamethasone shows a favorable benefit-risk profile for patients with relapsed or refractory (R/R) multiple myeloma (MM), according to a new study. “The more convenient dosing schedule can improve access to an efficacious therapy for patients unable to make twice-weekly visits to the... [Read Article]
Print Friendly, PDF & Email

Encouraging early results for CB-derived NK cells in MM

Print Friendly, PDF & Email


Attendees at ASCO 2018
©ASCO/Todd Buchanan 2018
Cord blood (CB) is a viable source of natural killer (NK) cells for adoptive cellular therapy for multiple myeloma (MM), according to a speaker at the 2018 ASCO Annual Meeting. Ex-vivo expanded cord blood NK cells were well tolerated without significant graft-versus-host disease (GVHD) or cytokine release syndrome... [Read Article]
Print Friendly, PDF & Email